Company attributes
Other attributes
Bavarian Nordic is a Denmark-based company that develops, manufactures, and commercializes vaccines for diseases such as Covid-19, smallpox, and monkeypox. Commercialized products by Bavarian Nordic include the vaccines JYNNEOS/IMVAMUNE/IMVANEX for smallpox, Rabipur/RabAvert for rabies, Encepur for tick-borne encephalitis, and MVABEA for Ebola (licensed to Janssen).
Bavarian Nordic makes a smallpox vaccine called Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN), also known as JYNNEOS in the US, IMVANEX in Europe, and IMVAMUNE in Canada. Bavarian’s smallpox vaccine, which contains a live non-replicating virus, is approved in the US and Canada for monkeypox, which is related to smallpox. In Europe, the vaccine is approved for smallpox but used off-label for monkeypox.
Bavarian Nordic’s smallpox vaccine was developed under Project BioShield, a US program created by Congress in 2004 to purchase medicines and vaccines related to bioterrorism attacks. The vaccine was developed under contracts with the Biomedical Advanced Research and Development Authority (BARDA). The attenuated virus used for the smallpox vaccine, MVA-BN, is also used by Bavarian Nordic as an adaptable vaccine platform that can be modified and used to generate recombinant MVA-BN-based vaccines for other infectious diseases as well as cancer.
In response to the monkeypox outbreak in May 2022, Bavarian Nordic has supplied contracts for the smallpox/monkeypox vaccine with the US and Canada as well as other undisclosed countries. The vaccine is manufactured by Bavarian Nordic’s commercial-scale manufacturing facility in Kvistgaard, Denmark. A freeze-dried version of the vaccine with an improved shelf-life is expected in 2023.
Bavarian Nordic is developing a COVID-19 booster vaccine and a respiratory syncytial virus (RS) vaccine, which are in clinical research stages as of May 2022. Bavarian Nordic developed a capsid-virus-like particle vaccine called ABNCoV2 against SARS-CoV-2 and variants that cause Covid-19. ABNCoV2 was in phase 2 clinical trials as of May 2022.
